Welcome to our dedicated page for Skinhealth Systems news (Ticker: SKIN), a resource for investors and traders seeking the latest updates and insights on Skinhealth Systems stock.
SkinHealth Systems Inc. reports developments tied to its global medical aesthetics business, with recurring updates on financial results, margin performance, adjusted EBITDA, installed-base activity and its recurring consumables model. The company, formerly The Beauty Health Company, trades on the Nasdaq Capital Market under the symbol SKIN.
Company news also covers the Hydrafacial platform, SkinStylus microneedling and nano-channeling treatments, HydraScalp with Keravive, provider adoption, consumer skin-health research, board appointments and the completed corporate rebrand to SkinHealth Systems.
The Beauty Health Company (NASDAQ: SKIN) has launched the Hydrafacial™ Syndeo™ internationally after a successful U.S. introduction in March 2022. Syndeo combines Hydrafacial's patented vortex fusion technology with a cloud-based digital experience, allowing providers to personalize treatments based on client preferences and history. Over 3,000 Syndeo systems were sold in 2022, exceeding sales expectations. The product will debut at the Aesthetic & Anti-Aging Medicine World Congress in Monaco from March 30 to April 1, 2023, and will be available in select European and Asia-Pacific markets in April 2023.
The Beauty Health Company (NASDAQ: SKIN) reported a 41% year-over-year growth in net sales for 2022, reaching $365.9 million, exceeding market expectations for the eighth consecutive quarter. Adjusted EBITDA rose by 46% to $47.7 million, aligning with the previously guided range. For Q4 2022, net sales increased 26% year-over-year to $98.1 million, accompanied by a net income of $3.8 million. The company aims for 2023 net sales between $450 million to $470 million and confirms long-range 2025 guidance of $600 million to $700 million. Despite challenges, BeautyHealth's strategic focus on growth remains robust.
The Beauty Health Company (NASDAQ: SKIN) has entered a definitive agreement to acquire SkinStylus, an FDA-cleared microneedling device. This strategic acquisition aims to enhance BeautyHealth's portfolio as it strives to become a leading beauty, health, and wellness platform. Microneedling is expected to reach a U.S. market size of $1 billion by 2030 and is commonly offered alongside Hydrafacial treatments. The integration of SkinStylus is anticipated to provide opportunities for growth starting in 2024. Key opinions from company executives highlight the innovation and demand for microneedling in the aesthetic market.
Dior Beauty has partnered with The BeautyHealth Company (NASDAQ:SKIN) to launch a new exclusive experience called Dior powered by Hydrafacial. This treatment, debuting in April 2023 at Dior spas worldwide, combines Dior skincare with Hydrafacial technology. The 90-minute treatment incorporates the Dior Floral Peeling Lotion and Hydrafacial's patented vortex technology for enhanced skincare. BeautyHealth's CEO, Andrew Stanleick, highlighted the significance of this collaboration in creating innovative skincare experiences. This initiative aims to rejuvenate skin and promote wellness through effective treatment protocols.
The Beauty Health Company (NASDAQ:SKIN) has launched a new skincare booster in collaboration with Omorovicza. This Advanced Skin Renewal Booster, utilizing Omorovicza’s patented Healing Concentrate™, aims to rejuvenate the skin, enhancing Hydrafacial’s offerings. The booster is now available for providers across North America and EMEA. Key ingredients include Retinol, Vitamin C, Hyaluronic Acid, and Amino Acids, designed to improve skin texture and firmness. BeautyHealth's CEO, Andrew Stanleick, highlights this partnership as a strategic move to personalize skincare experiences, further enhancing the brand's growing booster portfolio.
The Beauty Health Company (NASDAQ:SKIN) has announced that it will release its fourth quarter and full-year fiscal 2022 results on February 28, 2023, before market opening. Following the release, the company will host an investor conference call at 8:30 a.m. Eastern Time. Investors and analysts can participate via a webcast available on their investor relations website. Beauty Health, known for its flagship brand Hydrafacial, provides innovative skincare solutions globally, available in over 90 countries with nearly 25,000 delivery systems.
The Beauty Health Company (NASDAQ: SKIN) announced that its Hydrafacial treatment significantly improves acne concerns, as per a study published in the Journal of Clinical and Aesthetic Dermatology. All study participants, aged 19 to 48, noted clearer, less inflamed skin following a series of treatments every two weeks over 12 weeks. Participants reported improved acne severity and a boost in self-confidence, with 100% feeling more confident by the study's end. The findings aim to encourage those suffering from acne to consider Hydrafacial's clarifying treatment.
The Beauty Health Company (NASDAQ:SKIN) has launched a new hydration booster in collaboration with BABOR Skincare, the DOCTOR BABOR Collagen HA booster. This product utilizes advanced formulations featuring collagen peptides and hyaluronic acid to enhance skin hydration and elasticity. The booster is designed to be used with Hydrafacial's patented delivery system, offering customization for various skin concerns. The product is now available across North America, expanding Hydrafacial's lineup of over 20 customizable boosters.
The Beauty Health Company (NASDAQ: SKIN) announced that CEO Andrew Stanleick and CFO Liyuan Woo will participate in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 9:10 a.m. ET in New York, NY. The discussion will be available via live webcast on the company’s investor relations website, with an archived replay and transcript accessible after the event. Beauty Health focuses on innovative beauty health experiences through its flagship brand, HydraFacial, which operates in over 90 countries with nearly 25,000 delivery systems.
The Beauty Health Company (NASDAQ: SKIN) has announced a $100 million accelerated share repurchase (ASR) agreement with JP Morgan Chase Bank. This buyback follows a prior repurchase program initiated on September 27, 2022, with $100 million remaining as of November 9, 2022. Under the ASR, Beauty Health expects to receive approximately 9.5 million shares on November 14, 2022. The company will fund the repurchase using available cash and anticipates a strong financial position post-buyback, reinforcing confidence in its business growth and infrastructure investments.